Crofelemer - Napo Pharmaceuticals

Drug Profile

Crofelemer - Napo Pharmaceuticals

Alternative Names: CRO-HIV; CRO-IBS; CRO-ID; CRO-PED; Fulyzaq; Mytesi; Provir; SP 303; TRN-002; Virend

Latest Information Update: 03 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shaman Pharmaceuticals
  • Developer Napo Pharmaceuticals; Puma Biotechnology; Shaman Pharmaceuticals; University of California at San Francisco
  • Class Antidiarrhoeals; Biopolymers; Chromans; Flavonoids; Phytotherapies
  • Mechanism of Action Chloride channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diarrhoea
  • Phase II Irritable bowel syndrome
  • Preclinical Short bowel syndrome
  • Discontinued Herpes simplex virus infections; Influenza virus infections

Most Recent Events

  • 24 Sep 2018 Crofelemer licensed to Knight Therapeutics in Canada and Israel
  • 28 Jun 2018 RedHill Biopharma and Napo Pharmaceuticals agree to co-promote crofelemer in USA for Diarrhoea
  • 22 Jan 2018 Napo Pharmaceuticals announces intention to submit application to the US FDA for the planned formulation of crofelemer for congenital diarrhoeal disorders in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top